


# Patent Claims


1. A compound of formula I

5



10

in which



15

X is H, -OH, -OA, phenoxy, Ar, -O-CO-A, SO<sub>3</sub>H, SO<sub>3</sub>A, -OSO<sub>3</sub>H, -OSO<sub>3</sub>A, -OSO<sub>2</sub>A, SO<sub>2</sub>A, Hal, COOH, COOA, CONH<sub>2</sub>, NHSO<sub>2</sub>A, COA, CHO or SO<sub>2</sub>NH<sub>2</sub>, or

two radicals X together are methylenedioxy or ethylenedioxy,

20

R<sup>1</sup> is H, A, -OH, -OA or Hal, or

two radicals R<sup>1</sup> together are methylenedioxy or ethylenedioxy,

Y is CH or N,

Ar is phenyl which is unsubstituted or monosubstituted, disubstituted or trisubstituted by A,

25

A is an unbranched or branched alkyl having 1-10 carbon atoms, in which 1-7 H atoms may be replaced by F,

Hal is F, Cl, Br or I,

n is 1, 2, 3 or 4, and

30

m is 1, 2, 3, 4 or 5, or

a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

35


2. A compound according to Claim 1,

in which

X is H, -OH or -OA, or


two radicals X together are methylenedioxy or ethylenedioxy, or  
a salt or a solvate or a mixture of stereoisomers or isolated  
stereoisomer thereof.

- 5  
3. A compound according to Claim 1,  
in which




- 10  
X is H, -OH or -OA, or  
two radicals X together are methylenedioxy or ethylenedioxy, or  
a salt or a solvate or a mixture of stereoisomers or isolated  
15  
stereoisomer thereof.

4. A compound according to Claim 1,  
in which



- X is H, -OH or -OA,  
Y is N,  
25  
R¹ is A,  
A is an unbranched or branched alkyl having 1-6 carbon  
atoms,  
n is 1, 2, 3 or 4, and  
m is 1, 2, 3 or 4, or  
30  
a salt or a solvate or a mixture of stereoisomers or isolated  
stereoisomer thereof.

5. A compound according to Claim 1,  
35  
in which



- 5 X is H, -OH or -OA,  
R<sup>1</sup> is A,  
A is an unbranched or branched alkyl having 1-6 carbon atoms,  
n is 1, 2, 3 or 4, and  
10 m is 1, 2, 3 or 4, or  
a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.
- 15 6. A compound according to Claim 1 selected from  
6-hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]chromone,  
7-hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]chromone, or  
6-hydroxy-2-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]chromone,  
20 a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.
- 25 7. A pharmaceutical composition comprising a compound according to  
Claim 1 or a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof and one or more pharmaceutically acceptable excipients and/or adjuvants.
- 30 8. A method of inhibiting tyrosine kinase comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 35 9. A method of treating a solid tumor in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

- 5
10. A method according to Claim 9, wherein the solid tumor is a cerebral tumor, a tumor of the genito-urinary tract, a tumor of the lymphatic system, a stomach tumor, a laryngeal tumor or a lung tumor.
- 10
11. A method according to Claim 9, wherein the solid tumor is monocytic leukaemia, lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, glioblastoma or breast carcinoma.
- 15
12. A method of treating a disease by inhibiting angiogenesis in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 20
13. A method according to Claim 12, wherein the disease is an ocular disease.
- 25
14. A method of treating retinal vascularisation in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 30
15. A method of treating diabetic retinopathy in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 35
16. A method of treating an age-related macular degeneration in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
17. A method of treating an inflammatory disease in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

18. A method according to claim 17, wherein the inflammatory disease is rheumatoid arthritis, psoriasis, contact dermatitis or a delayed hypersensitivity reaction.
- 5 19. A method of treating a tyrosine kinase-dependent disease or a tyrosine kinase-dependent condition in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 10 20. A method of treating a bone pathology comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 15 21. A method according to claim 20, wherein the bone pathology is osteosarcoma, osteoarthritis or rickets.
- 20 22. A pharmaceutical composition according to claim 7, further comprising an additional pharmaceutically active compound.
23. A kit comprising separate packs of  
(a) a pharmaceutical composition according to Claim 7 or a  
25 compound of formula I or a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof,  
and  
(b) an additional pharmaceutically active compound or composition.
- 30 24. A method according to claim 9, further comprising administering an oestrogen receptor modulator, an androgen receptor modulator, a retinoid receptor modulator, a cytotoxic agent, an antiproliferative agent, a prenyl-protein transferase inhibitor, an HMG-CoA reductase  
35 inhibitor, an HIV protease inhibitor, a reverse transcriptase inhibitor or an angiogenesis inhibitor.

25. A method according to claim 24, further comprising performing radiotherapy on said mammal.

5 26. A method of treating a disease related to an oxidative stress condition in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

10 27. A method according to claim 25, wherein the disease is memory loss or a neurodegenerative disorder.

28. A food supplement comprising a compound of claim 1.

15 29. A cosmetic composition comprising a compound of claim 1.


30. A method of protecting the proteins of the skin from stress comprising applying a cosmetic composition of claim 29 to the skin.

20 31. A topically applicable cosmetic composition comprising a compound of claim 1.

25 32. A cosmetic composition according to claim 29, containing 0.0001 to 50% by weight of a compound of claim 1.

33. A compound of formula VI

30




VI

35


in which

X is -H, -OH, -OA, phenoxy, Ar, -O-CO-A, SO<sub>3</sub>H, SO<sub>3</sub>A, -OSO<sub>3</sub>H, -OSO<sub>3</sub>A, -OSO<sub>2</sub>A, SO<sub>2</sub>A, Hal, COOH, COOA, CONH<sub>2</sub>, NHSO<sub>2</sub>A, COA, CHO or SO<sub>2</sub>NH<sub>2</sub>, or  
two radicals X together are methylenedioxy or ethylenedioxy, and  
n is 1, 2, 3 or 4, or  
a salt thereof.


34. A process for preparing a compound according to Claim 1 or a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof, comprising  
a) reacting a compound of formula II



in which  
X and n are as defined in Claim 1,  
with a compound of formula III




in which A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,  
to give a compound of formula IV




in which X and n are as defined in Claim 1,  
and A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

10  
b) then hydrolysing the compound of formula IV to a compound of  
formula V



20  
in which X and n are as defined in Claim 1,

c) then converting the compound of formula V to a compound of  
formula VI




30  
in which X and n are as defined in Claim 1,

and then either

35  
reacting the compound of formula VI with a compound of formula VII






VII

in which R is as defined in Claim 1,  
to give a compound of formula I,

or reacting the compound of formula V with a compound of formula  
VII



VII

in which R is as defined in Claim 1,  
in a two-step, one-pot reaction to give a compound of formula I,  
and/or  
d) a compound of formula I is converted into a salt or into a solvate  
and/or a stereoisomer of a compound of formula I is isolated.